{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:47:27Z","timestamp":1784814447540,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Recurrence remains a major obstacle to long-term survival of laryngeal squamous cell carcinoma (LSCC). We conducted a genome-wide integrated analysis of methylation and the transcriptome to establish methylation-driven genes prognostic signature (MDGPS) to precisely predict recurrence probability and optimize therapeutic strategies for LSCC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>LSCC DNA methylation datasets and RNA sequencing (RNA-seq) dataset were acquired from the Cancer Genome Atlas (TCGA). MethylMix was applied to detect DNA methylation-driven genes (MDGs). By univariate and multivariate Cox regression analyses, five genes of DNA MDGs was developed a recurrence-free survival (RFS)-related MDGPS. The predictive accuracy and clinical value of the MDGPS were evaluated by receiver operating characteristic (ROC) and decision curve analysis (DCA), and compared with TNM stage system. Additionally, prognostic value of MDGPS was validated by external Gene Expression Omnibus (GEO) database. According to 5 MDGs, the candidate small molecules for LSCC were screen out by the CMap database. To strengthen the bioinformatics analysis results, 30 pairs of clinical samples were evaluated by digoxigenin-labeled chromogenic in situ hybridization (CISH).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 88 DNA MDGs were identified, and five RFS-related MDGs (LINC01354, CCDC8, PHYHD1, MAGEB2 and ZNF732) were chosen to construct a MDGPS. The MDGPS can effectively divide patients into high-risk and low-risk group, with the area under curve (AUC) of 0.738 (5-year RFS) and AUC of 0.74 (3-year RFS). Stratification analysis affirmed that the MDGPS was still a significant statistical prognostic model in subsets of patients with different clinical variables. Multivariate Cox regression analysis indicated the efficacy of MDGPS appears independent of other clinicopathological characteristics. In terms of predictive capacity and clinical usefulness, the MDGPS was superior to traditional TNM stage. Additionally, the MDGPS was confirmed in external LSCC cohorts from GEO. CMap matched the 9 most significant small molecules as promising therapeutic drugs to reverse the LSCC gene expression. Finally, CISH analysis in 30 LSCC tissues and paired adjacent normal tissues revealed that MAGEB2 has significantly higher expression of LSCC compared to adjacent non-neoplastic tissues; LINC01354, CCDC8, PHYHD1, and ZNF732 have significantly lower expression of LSCC compared to adjacent non-neoplastic tissues, which were in line with bioinformatics analysis results.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>A MDGPS, with five DNA MDGs, was identified and validated in LSCC patients by combining transcriptome and methylation datasets analysis. Compared TNM stage alone, it generates more accurate estimations of the recurrence prediction and maybe offer novel research directions and prospects for individualized treatment of patients with LSCC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12935-020-01567-3","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T15:04:28Z","timestamp":1601391868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Identification and validation of methylation-driven genes prognostic signature for recurrence of laryngeal squamous cell carcinoma by integrated bioinformatics analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Jie","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waisheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-4396","authenticated-orcid":false,"given":"Genglong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"4","key":"1567_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.anl.2017.09.009","volume":"45","author":"AA Unsal","year":"2018","unstructured":"Unsal AA, Kilic S, Dubal PM, Baredes S, Eloy JA. A population-based comparison of European and North American sinonasal cancer survival. Auris Nasus Larynx. 2018;45(4):815\u201324.","journal-title":"Auris Nasus Larynx"},{"issue":"1","key":"1567_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD. Cancer statistics, 2020. Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"Cancer J Clin."},{"key":"1567_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/CMAR.S115761","volume":"9","author":"C Lo Nigro","year":"2017","unstructured":"Lo Nigro C, Denaro N, Merlotti A, Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017;9:363\u201371.","journal-title":"Cancer Manag Res"},{"key":"1567_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijsu.2020.03.010","volume":"76","author":"J Cui","year":"2020","unstructured":"Cui J, Wang L, Tan G, et al. Development and validation of nomograms to accurately predict risk of recurrence for patients with laryngeal squamous cell carcinoma: Cohort study. Int J Surg. 2020;76:163\u201370.","journal-title":"Int J Surg"},{"key":"1567_CR5","first-page":"5980567","volume":"2019","author":"J Cui","year":"2019","unstructured":"Cui J, Wen Q, Tan X, Chen Z. A genomic-clinicopathologic nomogram predicts survival for patients with laryngeal squamous. Cell Carcinoma. 2019;2019:5980567.","journal-title":"Cell Carcinoma"},{"issue":"3","key":"1567_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.molonc.2014.10.012","volume":"9","author":"OA Stefansson","year":"2015","unstructured":"Stefansson OA, Moran S, Gomez A, Sayols S, Arribas-Jorba C, Sandoval J, Hilmarsdottir H, Olafsdottir E, Tryggvadottir L, Jonasson JG, et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol Oncol. 2015;9(3):555\u201368.","journal-title":"Mol Oncol"},{"key":"1567_CR7","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1038\/ncomms10478","volume":"7","author":"AE Teschendorff","year":"2016","unstructured":"Teschendorff AE, Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, Fasching PA, Widschwendter M. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat Commun. 2016;7:10478.","journal-title":"Nat Commun"},{"issue":"4","key":"1567_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s13167-019-00189-8","volume":"10","author":"M Bao","year":"2019","unstructured":"Bao M, Shi R, Zhang K, Zhao Y, Wang Y. Development of a membrane lipid metabolism-based signature to predict overall survival for personalized medicine in ccRCC patients. EPMA J. 2019;10(4):383\u201393.","journal-title":"EPMA J"},{"issue":"24","key":"1567_CR9","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.7150\/thno.31155","volume":"9","author":"J Long","year":"2019","unstructured":"Long J, Chen P, Lin J, Bai Y, Yang X, Bian J, Lin Y, Wang D, Yang X, Zheng Y, et al. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 2019;9(24):7251\u201367.","journal-title":"Theranostics"},{"key":"1567_CR10","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1136\/bmj.i6","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:i6.","journal-title":"BMJ"},{"issue":"1","key":"1567_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12957-018-1349-y","volume":"16","author":"Z Shen","year":"2018","unstructured":"Shen Z, Lin L, Cao B, Zhou C, Hao W, Ye D. LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma. World J Surg Oncol. 2018;16(1):42.","journal-title":"World J Surg Oncol"},{"issue":"206","key":"1567_CR12","first-page":"1248","volume":"2016","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhang ZX, Chen S, Qiu GB, Xu ZM, Fu WN. Methylation status of SP1 Sites within miR-23a-27a-24\u20132 promoter region influences laryngeal cancer cell proliferation and apoptosis. Biomed Res Int. 2016;2016(206):1248.","journal-title":"Biomed Res Int."},{"issue":"8","key":"1567_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/cbf.3233","volume":"34","author":"S Jili","year":"2016","unstructured":"Jili S, Eryong L, Lijuan L, Chao Z. RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under the regulation of miR-148a-3p\/DNMT1 axis. Cell Biochem Funct. 2016;34(8):597\u2013605.","journal-title":"Cell Biochem Funct"},{"issue":"7","key":"1567_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.2016.68.2153","volume":"35","author":"J Qiu","year":"2017","unstructured":"Qiu J, Peng B, Tang Y, et al. CpG Methylation signature predicts recurrence in early-stage hepatocellular carcinoma: results from a multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(7):734\u201342.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"1567_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/cncr.31087","volume":"124","author":"CW Hoban","year":"2018","unstructured":"Hoban CW, Beesley LJ, Bellile EL, et al. Individualized outcome prognostication for patients with laryngeal cancer. Cancer. 2018;124(4):706\u201316.","journal-title":"Cancer"},{"key":"1567_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.oraloncology.2018.01.001","volume":"78","author":"RJLM Te Riele","year":"2018","unstructured":"Te Riele RJLM, Dronkers EAC, Wieringa MH, et al. Influence of anemia and BMI on prognosis of laryngeal squamous cell carcinoma: Development of an updated prognostic model. Oral Oncol. 2018;78:25\u201330.","journal-title":"Oral Oncol"},{"issue":"17","key":"1567_CR17","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/bioinformatics\/bty156","volume":"34","author":"PL Cedoz","year":"2018","unstructured":"Cedoz PL, Prunello M, Brennan K, Gevaert O. MethylMix 2.0: an R package for identifying DNA methylation genes. Bioinformatics. 2018;34(17):3044\u20136.","journal-title":"Bioinformatics."},{"key":"1567_CR18","doi-asserted-by":"crossref","unstructured":"Berger DM, Wassenberg RM, Jozwiak K, Wiel BA, Balm JM, Berg JG, Klop WM. Inter-observer variation in the histopathology reports of head and neck melanoma; a comparison between the seventh and eighth edition of the AJCC staging system. Eur J Surg Oncol. 2019;45(2):235\u2013241.","DOI":"10.1016\/j.ejso.2018.10.529"},{"issue":"1","key":"1567_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13046-019-1150-y","volume":"38","author":"J Li","year":"2019","unstructured":"Li J, He M, Xu W, Huang S. LINC01354 interacting with hnRNP-D contributes to the proliferation and metastasis in colorectal cancer through activating Wnt\/beta-catenin signaling pathway. J Exp Clin Cancer Res. 2019;38(1):161.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"1567_CR20","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1002\/cam4.1627","volume":"7","author":"W Lu","year":"2018","unstructured":"Lu W, Xu Y, Xu J, Wang Z, Ye G. Identification of differential expressed lncRNAs in human thyroid cancer by a genome-wide analyses. Cancer Med. 2018;7(8):3935\u201344.","journal-title":"Cancer Med"},{"issue":"10","key":"1567_CR21","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI129107","volume":"129","author":"P Wang","year":"2019","unstructured":"Wang P, Yan F, Li Z, Yu Y, Parnell SE, Xiong Y. Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development. J Clin Investig. 2019;129(10):4393\u2013407.","journal-title":"J Clin Investig"},{"key":"1567_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13148-015-0089-x","volume":"7","author":"RP Pangeni","year":"2015","unstructured":"Pangeni RP, Channathodiyil P, Huen DS, Eagles LW, Johal BK, Pasha D, Hadjistephanou N, Nevell O, Davies CL, Adewumi AI, et al. The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clin Epigenet. 2015;7:57.","journal-title":"Clin Epigenet"},{"issue":"3","key":"1567_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbrc.2016.03.039","volume":"472","author":"Y Furusawa","year":"2016","unstructured":"Furusawa Y, Kubo T, Fukazawa T. Phyhd1, an XPhyH-like homologue, is induced in mouse T cells upon T cell stimulation. Biochem Biophys Res Commun. 2016;472(3):551\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"1567_CR24","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.2147\/OTT.S159491","volume":"11","author":"S Jin","year":"2018","unstructured":"Jin S, Cao S, Li J, et al. Cancer\/testis antigens (CTAs) expression in resected lung cancer. OncoTargets Therapy. 2018;11:4491\u20139.","journal-title":"OncoTargets Therapy."},{"issue":"2","key":"1567_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jdermsci.2015.11.004","volume":"81","author":"Y Nobeyama","year":"2016","unstructured":"Nobeyama Y, Nakagawa H. Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1. J Dermatol Sci. 2016;81(2):118\u201323.","journal-title":"J Dermatol Sci"},{"key":"1567_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2017.03.029","volume":"396","author":"A Van Tongelen","year":"2017","unstructured":"Van Tongelen A, Loriot A, De Smet C. Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes. Cancer Lett. 2017;396:130\u20137.","journal-title":"Cancer Lett"},{"issue":"9","key":"1567_CR27","doi-asserted-by":"publisher","first-page":"e45534","DOI":"10.1371\/journal.pone.0045534","volume":"7","author":"KM Pattani","year":"2012","unstructured":"Pattani KM, Soudry E, Glazer CA, Ochs MF, Wang H, Schussel J, Sun W, Hennessey P, Mydlarz W, Loyo M, et al. MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma. PLoS ONE. 2012;7(9):e45534.","journal-title":"PLoS ONE"},{"issue":"11","key":"1567_CR28","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1940-6207.CAPR-10-0037","volume":"3","author":"S Reuter","year":"2010","unstructured":"Reuter S, Prasad S, Phromnoi K, Ravindran J, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, Aggarwal BB. Thiocolchicoside exhibits anticancer effects through downregulation of NF-kappaB pathway and its regulated gene products linked to inflammation and cancer. Cancer Prev Res. 2010;3(11):1462\u201372.","journal-title":"Cancer Prev Res"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01567-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-020-01567-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01567-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:10:42Z","timestamp":1632870642000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-020-01567-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1186\/s12935-020-01567-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the data was obtained from TCGA and GEO, and the informed consent had been attained from the patients before our study. The studies involving human tissues samples were reviewed and approved by the Research Ethics Committee of Affiliated Cancer Hospital & Institute of Guangzhou Medical University, and complied with the Declaration of Helsinki. All patients were aware of the present study and signed an informed consent agreement.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}